Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
F 1.00 -2.91% -0.03
NKTR closed down 2.91 percent on Wednesday, November 20, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -2.91%
Narrow Range Bar Range Contraction -2.91%
Lower Bollinger Band Walk Weakness -2.91%
Wide Bands Range Expansion -2.91%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
Down 1% about 17 hours ago
Rose Above Previous Day's High about 22 hours ago
Rose Above Lower Bollinger Band about 22 hours ago
Up 3% about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nektar Therapeutics Description

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmaceutical Immunology Pain Drugs Clinical Development Breast Cancer Pharmacology Antibiotics Opioids Ovarian Cancer Chronic Pain Treatment Of Breast Cancer Colorectal Cancer Cytokine Acute Pain Morphinans Constipation Neuropathic Pain Treatment Of Chronic Pain Anti Infectives Pegylation Metastatic Colorectal Cancer Aminoglycoside Metastatic Breast Cancer Nektar Therapeutics Opioid Antagonists Opioid Induced Constipation Pneumonia

Is NKTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.928
52 Week Low 0.4227
Average Volume 1,430,676
200-Day Moving Average 1.23
50-Day Moving Average 1.28
20-Day Moving Average 1.26
10-Day Moving Average 1.20
Average True Range 0.09
RSI (14) 30.07
ADX 26.19
+DI 18.48
-DI 29.55
Chandelier Exit (Long, 3 ATRs) 1.20
Chandelier Exit (Short, 3 ATRs) 1.27
Upper Bollinger Bands 1.51
Lower Bollinger Band 1.00
Percent B (%b) 0.0
BandWidth 41.10
MACD Line -0.07
MACD Signal Line -0.03
MACD Histogram -0.0404
Fundamentals Value
Market Cap 190.77 Million
Num Shares 191 Million
EPS -1.55
Price-to-Earnings (P/E) Ratio -0.65
Price-to-Sales 1.53
Price-to-Book 0.85
PEG Ratio 3.22
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.11
Resistance 3 (R3) 1.12 1.09 1.09
Resistance 2 (R2) 1.09 1.07 1.09 1.08
Resistance 1 (R1) 1.05 1.05 1.04 1.04 1.08
Pivot Point 1.02 1.02 1.02 1.02 1.02
Support 1 (S1) 0.98 1.00 0.97 0.97 0.92
Support 2 (S2) 0.95 0.98 0.95 0.92
Support 3 (S3) 0.91 0.95 0.91
Support 4 (S4) 0.90